Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096291 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00096291: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00096291 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096291, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before and after surgery may shrink the tumor so it can be removed and may kill any tumor cells remaining after surgery. PURPOSE: This randomized phase II trial is comparing two different regimens of doxorubicin and paclitaxel to see how well they work in treating women who are undergoing surgery for breast cancer.
Interventions
- OTHER Doxorubicin followed by Paclitaxel
- OTHER Paclitaxel followed by Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2000-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096291
The ClinicalTrials.gov registry entry for NCT00096291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxorubicin followed by Paclitaxel is the first listed.
NCT00096291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096291 about?
NCT00096291 is a clinical study titled "Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as doxorubicin and paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before and after surgery may shrink the tumor so it can be removed and may kill any tumor cells remaining after surgery...
What is the current status of trial NCT00096291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2000-02.
What interventions are being tested in trial NCT00096291?
The interventions under investigation include: Doxorubicin followed by Paclitaxel (OTHER), Paclitaxel followed by Doxorubicin (OTHER).
Who is sponsoring clinical trial NCT00096291?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.